Verona Pharma Acquisition Nears Final Approval as Market Awaits Completion

The pharmaceutical sector is closely monitoring the impending acquisition of Verona Pharma by industry giant Merck & Co., a transaction valued at approximately $10 billion. Market activity indicates near-certainty regarding the deal’s completion, with Verona’s share price trading consistently near the agreed acquisition price in recent sessions. This stability suggests investors perceive minimal risk of the arrangement falling through.

Financing Secured for Major Pharmaceutical Transaction

Merck has taken concrete steps to solidify the acquisition, successfully placing $6 billion in bonds late last week to secure the necessary financing. This decisive move underscores the company’s commitment to the transaction, which is anticipated to finalize in the fourth quarter of 2025. The agreed-upon terms set the purchase price at $107 per American Depositary Share (ADS) of Verona Pharma.

Breakthrough Drug Drives Deal Valuation

At the core of this significant deal is Ohtuvayre, Verona’s innovative chronic obstructive pulmonary disease (COPD) treatment. The drug achieved a critical milestone with its FDA approval in June 2024, representing the first novel inhalation therapy in over twenty years that combines both bronchodilator and anti-inflammatory properties within a single molecule. Recent financial performance highlights its commercial potential: Verona reported quarterly earnings of $0.13 per share, significantly surpassing expectations of a $0.01 loss, while generating revenue exceeding $103 million.

Should investors sell immediately? Or is it worth buying Verona Pharma?

Mixed Signals from Market Analysts

Following the acquisition announcement, several brokerage firms have adjusted their ratings on Verona to “Hold” or “Neutral,” citing limited upside potential given the fixed acquisition price. Despite this cautious stance, the average price target among fourteen analysts remains at $109, slightly above Merck’s offer price. This institutional perspective contrasts with substantial position increases by major investment firms including Adage Capital and Baker BROS.

With the stock trading marginally below the formal acquisition price, market participants appear to be anticipating smooth regulatory approval. The final significant hurdle remains clearance from British antitrust authorities, with investors watching closely for this definitive green light.